Are Investors Undervaluing Cardinal Health (CAH) Right Now?

Zacks analysis indicates Cardinal Health (CAH) may be undervalued, assigning it a Zacks Rank #2 (Buy) and an 'A' Value grade. The company's PEG ratio of 1.63 and P/CF ratio of 16.98 are both favorable compared to industry averages of 1.75 and 17.32, respectively. These metrics, alongside a positive earnings outlook, suggest CAH represents a compelling value opportunity for investors.

Analysis

According to a Zacks analysis, Cardinal Health (CAH) is presented as a potentially undervalued investment opportunity, meriting a Zacks Rank #2 (Buy) and a Value grade of 'A'. The firm's valuation appears favorable on a relative basis, with a Price-to-Earnings-Growth (PEG) ratio of 1.63, below the industry average of 1.75. This suggests the stock's price is attractive relative to its expected earnings growth. This thesis is further supported by the company's Price-to-Cash-Flow (P/CF) ratio of 16.98, which is also slightly more attractive than the industry's 17.32 average, pointing to a solid cash outlook. While these metrics are favorable compared to peers, they are currently trading above their 12-month medians of 1.48 (PEG) and 15.08 (P/CF). The positive outlook is ultimately anchored in the combination of these valuation metrics and a strong earnings forecast, positioning CAH as a noteworthy value stock.

Key Decisions for Investors

• Investors with a value-focused mandate should consider CAH based on its 'Buy' rating and valuation metrics that are favorable relative to its industry peers.
• The investment thesis is heavily contingent on a strong earnings outlook, so a key risk to monitor will be any negative revisions to earnings estimates or guidance in future reports.
• While the stock appears undervalued on a relative basis, investors should note that its current PEG and P/CF ratios are above their 12-month medians, indicating the valuation is not at its cheapest point over the past year.